Table 3 Published clinical trials of MSCs in patients with IPF
Author [References] | Research time (clinical study staging) | Number of samples (the degree of IPF) | MSCs type | Number of injected cells (× 106) | Evaluation index | Serious adverse reaction (follow-up time) | ||
|---|---|---|---|---|---|---|---|---|
Lung function(FVC, DLCO, PaO2) | 6MWD | CT chest | ||||||
Chambers DC.[50] | 2014 (phase Ib) | 8 (moderate IPF) | Placenta-derived MSCs | 1 or 2 /kg | No deterioration compared to baseline | No (6Â months) | ||
Tzouvelekis A.[51] | 2010.6–2011.9 (phase Ib) | 14 (mild to moderate IPF) | Adipose-derived MSCs | 0.5 /kg (three times) | No deterioration compared to baseline | No (12 months) | ||
Glassberg MK. [52] | 2013.11–2014.10 (phase I) | 9 (mild to moderate IPF) | Bone marrow–derived MSCs | 20 or 100 or 200 | No deterioration compared to baseline | No (15 months) | ||
Campo A. [53] | 2013–2016 (phase I) | 13 (mild to moderate IPF) | Bone marrow autologous MSCs | 10 or 50 or 100 | No deterioration compared to baseline | No (12 months) | ||
Averyanov A. [54] | 2019 (phase I) | 10 (moderate to severe IPF) | Bone marrow MSCs | 1600 | Significant improvement for the 6-MWD and lung function compared to baseline | No (12Â months) | ||